Beranda › Poliemia Vera › North Carolina
Uji klinis Poliemia Vera di North Carolina
6 studi untuk Poliemia Vera mencari peserta di lokasi di North Carolina.
Kota di North Carolina
Teks studi resmi (Bahasa Inggris)
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Atrium Health Cabarrus/LCI-Concord, Concord
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT06661915Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- University of North Carolina At Chapel Hill, Chapel Hill
- Levine Cancer Institute, Charlotte
- Duke University Medical Center, Department of Hematologic Malignancies and Cellular Therapy, Durham
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Jul 2026 · NCT07441694Registry of Older Patients With Cancer
- Seby B. Jones Cancer Center, Boone
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
- East Carolina University, Greenville
- dan 4 lainnya
Menerima pesertaStudi observasional
Usia 65 ke atas · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT01137825A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
- DUHS Duke Blood Cancer Center ( Site 6005), Durham
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Apr 2026 · NCT06351631Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
- University of North Carolina at Chapel Hill, Chapel Hill
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Mar 2026 · NCT06093672Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
Menerima pesertaStudi observasional
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 27 Okt 2025 · NCT01137643Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.